Lilly’s Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer’s Disease
HO
Press Releases
Eli Lilly and Company  
December 18, 2024

Lilly’s Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer’s Disease

China is the fourth major market where Kisunla has received approval

logo salamanca press

Salamanca Press

Local & Social